Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors.
The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma,S. R.L.
The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019.
Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | -4.28 Decreased by -470.16% | - |
| Aug 14, 23 | -6.99 Increased by +56.88% | - |
| May 15, 23 | -331.04 Decreased by -1.35 K% | -0.58 Decreased by -56.98 K% |
| Mar 29, 23 | 0.00 Increased by +100.00% | -0.56 Increased by +100.00% |
| Nov 14, 22 | -0.75 Decreased by -87.50% | -0.56 Decreased by -33.93% |
| Aug 12, 22 | -16.20 Decreased by -2.28 K% | -11.40 Decreased by -42.11% |
| Apr 8, 22 | -22.80 Decreased by -4.20 K% | -11.40 Decreased by -100.00% |
| Mar 11, 22 | -12.00 Decreased by -2.35 K% | -7.80 Decreased by -53.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -7.43 M Decreased by -77.30% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -6.91 M Decreased by -2.17% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -6.15 M Increased by +12.86% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -4.69 M Increased by +33.63% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -4.19 M Increased by +72.64% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -6.76 M Increased by +19.83% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -7.05 M Increased by +33.66% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -7.07 M Decreased by -15.40% | Decreased by N/A% Decreased by N/A% |